To include your compound in the COVID-19 Resource Center, submit it here.

Amnestix Inc., Sygnis Pharma deal

Sygnis acquired Amnestix for about €4 million ($5.6 million) in cash

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE